{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000877","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.762213+00:00","generated_at":"2026-06-06T05:28:20.079816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IRADIMED reports record Q4 revenue $17.5M (+17.4%); initiates quarterly dividend; FY24 guidance $72-74M","bullets":["Record Q4 2023 revenue $17.5M (+17.4% YoY); GAAP diluted EPS $0.36 vs $0.29, non-GAAP $0.39 vs $0.32.","Full-year 2023 revenue $65.6M (+23% YoY); GAAP EPS $1.35, non-GAAP EPS $1.48; operating income $20.0M (+28.2%).","Guidance Q1 2024: rev $17.0-17.3M, GAAP EPS $0.29-0.31, non-GAAP $0.33-0.35. FY2024: rev $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62.","CEO announces initiation of a quarterly dividend in 2024 (amount and record date not specified in release).","Operating cash flow for FY2023 $13.5M vs $10.0M; expects ~$13M capex for new Orlando facility in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000877","json":"https://secwatch.observer/filing/0001558370-24-000877.json","markdown":"https://secwatch.observer/filing/0001558370-24-000877.md","text":"https://secwatch.observer/filing/0001558370-24-000877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/0001558370-24-000877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/irmd-20240208x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:28:20.079816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2907e551f8e1f5582a04f1d4dd19768f5476ef98","claim":"IRADIMED CORP reported the fourth quarter and full year ended December 31, 2023 results: revenue $17.5 million for the fourth quarter and $65.6 million for the full year of 2023, net income $4.5 million, or $0.36 per diluted share, EPS $0.36. Guidance initiated.","evidence_excerpt":"IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results ● Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024000877/0001558370-24-000877-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$17.5 million for the fourth quarter and $65.6 million for the full year of 2023"},{"label":"Net income","value":"$4.5 million, or $0.36 per diluted share"},{"label":"EPS","value":"$0.36"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}